We contribute to medical care through innovative drug discovery using the technologies of cell-free membrane protein preparation and non-canonical amino acid incorporation into target proteins.




CompanyLiberoThera Co., Ltd.
Registered OfficeNihonbashi Life Science Bldg.
2-3-11 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023, Japan
Tsurumi OfficeLeading Venture Plaza 1, Rm510
75-1 Onomachi, Tsurumi-ku, Yokohama 230-0046, JAPAN
TEL: +81 45-633-4725 FAX: +81 45-633-8617
Nihonbashi Laboratoryc/o Beyond BioLAB TOKYO
Nihonbashi Life Science Building B1
2-3-11 Nihonbashi-honcho
Chuo-ku, Tokyo 103-0023, JAPAN
EstablishmentApril 3, 2018
CEOToru Kanke, Ph.D.
BusinessDrug discovery targeting on membrane proteins and drug discovery services
Capital70,000,000 yen
Number of Officers & Employees7
Main BankMizuho Bank Ltd., MUFG Bank, Ltd.
Corporate History
2017 JanuaryLiberoThera’s founders took second place at BRAVE Pitch Contest.
2017 JanuaryLiberoThera’s founders were awarded a Prize of Mitsui Fudosan Life Science.
2017 OctoberJapan Science and Technology Agency (JST) accepted LiberoThera’s founders’ proposal “Acceleration of novel drug development using cell-free membrane protein preparation technology and non-canonical amino acid incorporation technology”.
2018 AprilFounded at Nihonbashi-honcho, Chuo-ku, Tokyo.
2018 JulyNew Energy and Industrial Technology Development Organization (NEDO) accepted LiberoThera’s proposal for “Commercialization Support Program for Seed-stage Technology-based Startups (NEDO-STS) “.
2018 NovemberLiberoThera opened an office in Yokohama (Tsurumi Office)
2019 FebruaryLiberoThera opened a research laboratory in Tokyo (Nihonbashi Laboratory)
2018 copyright LiberoThera Co., Ltd.